Stock Analysis on Net
Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Common-Size Income Statement 
Quarterly Data

Boston Scientific Corp., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Net sales 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of products sold -30.69 -31.15 -30.88 -31.17 -31.56 -31.08 -30.70 -30.71 -32.49 -36.89 -32.68 -39.49 -31.69 -29.27 -28.70 -28.81 -29.28 -28.43 -28.12 -29.68 -28.25
Gross profit 69.31% 68.85% 69.12% 68.83% 68.44% 68.92% 69.30% 69.29% 67.51% 63.11% 67.32% 60.51% 68.31% 70.73% 71.30% 71.19% 70.72% 71.57% 71.88% 70.32% 71.75%
Selling, general and administrative expenses -35.82 -35.87 -35.71 -35.88 -35.03 -36.87 -36.36 -36.43 -36.99 -37.96 -37.01 -39.84 -38.46 -37.60 -37.38 -36.79 -34.86 -37.25 -36.36 -35.54 -36.19
Research and development expenses -9.94 -10.18 -10.69 -10.33 -10.54 -10.23 -10.57 -9.68 -10.03 -10.56 -11.85 -12.08 -11.80 -10.61 -11.30 -10.64 -11.23 -11.25 -12.08 -11.04 -10.97
Royalty expense -0.32 -0.40 -0.35 -0.34 -0.40 -0.35 -0.48 -0.39 -0.44 -0.48 -0.45 -0.40 -0.47 -0.59 -0.55 -0.65 -0.64 -0.70 -0.71 -0.68 -0.76
Amortization expense -5.99 -6.14 -6.37 -6.29 -6.54 -6.14 -6.28 -5.85 -6.72 -7.16 -7.41 -9.84 -7.90 -6.89 -6.58 -6.12 -6.42 -6.36 -6.18 -5.90 -5.93
Goodwill impairment charges 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Intangible asset impairment charges 0.00 0.00 -3.94 -0.22 0.00 -6.30 -4.37 -1.46 0.00 -0.33 -8.24 -1.70 -7.79 -0.03 0.00 -1.41 -2.69 0.00 0.00 -1.37 -0.04
Contingent consideration net (expense) benefit -0.35 1.02 -0.63 -1.11 -0.40 0.61 0.89 2.76 0.22 -0.07 -0.23 0.00 4.25 0.86 -0.30 -0.38 1.12 0.35 0.54 0.16 -0.21
Restructuring charges -0.59 -0.15 -0.13 -0.34 -0.13 -0.74 -0.31 -0.10 -0.18 -1.29 -0.11 -0.20 -0.39 -0.96 -0.11 -0.04 -0.24 -0.59 -0.13 -0.20 -0.55
Litigation-related net (charges) credits 0.00 -4.04 0.00 -1.29 0.00 -4.09 0.00 -9.68 -0.15 -0.70 -9.74 0.00 0.00 -7.68 -0.92 -0.57 5.94 -3.32 -0.75 0.00 0.00
Gain (loss) on disposal of businesses and assets 0.00 -0.68 0.00 0.00 0.00 0.96 1.36 0.06 0.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating expenses -53.02% -56.45% -57.82% -55.80% -53.04% -63.16% -56.11% -60.77% -54.07% -61.26% -75.03% -64.05% -62.56% -63.50% -57.15% -56.59% -49.02% -59.12% -55.66% -54.58% -54.64%
Operating income (loss) 16.29% 12.40% 11.29% 13.04% 15.40% 5.76% 13.20% 8.51% 13.44% 1.85% -7.71% -3.54% 5.74% 7.23% 14.15% 14.60% 21.70% 12.46% 16.21% 15.74% 17.11%
Interest expense -1.92 -1.97 -1.99 -1.97 -9.22 -2.78 -2.93 -2.79 -2.98 -3.55 -3.23 -4.54 -3.46 -6.20 -3.51 -3.38 -4.37 -2.54 -2.42 -2.29 -2.56
Other, net -1.27 1.76 -1.58 -0.43 -1.02 0.83 6.21 -0.88 1.34 13.04 2.41 -0.95 -1.42 -1.24 -7.28 -5.70 1.00 1.64 5.27 0.48 -0.97
Other income (expense) -3.19% -0.22% -3.56% -2.40% -10.24% -1.95% 3.27% -3.67% -1.64% 9.49% -0.83% -5.49% -4.88% -7.44% -10.79% -9.08% -3.37% -0.90% 2.84% -1.81% -3.53%
Income (loss) before income taxes 13.10% 12.18% 7.73% 10.64% 5.16% 3.81% 16.47% 4.84% 11.81% 11.34% -8.54% -9.04% 0.87% -0.21% 3.36% 5.51% 18.33% 11.56% 19.06% 13.94% 13.58%
Income tax (expense) benefit -3.84 -7.87 -1.80 -2.62 -1.52 -0.77 -2.18 1.20 0.58 -3.62 2.71 1.70 -0.43 137.81 1.29 0.34 -1.32 3.51 -1.00 8.35 -1.05
Net income (loss) 9.27% 4.32% 5.93% 8.01% 3.64% 3.04% 14.29% 6.04% 12.39% 7.72% -5.83% -7.34% 0.43% 137.60% 4.65% 5.85% 17.01% 15.07% 18.05% 22.29% 12.53%
Preferred stock dividends -0.41 -0.46 -0.44 -0.43 -0.43 -0.45 -0.48 -0.45 -0.51 -0.48 -0.53 -0.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income (loss) available to common stockholders 8.85% 3.86% 5.49% 7.58% 3.21% 2.59% 13.81% 5.59% 11.88% 7.24% -6.36% -7.64% 0.43% 137.60% 4.65% 5.85% 17.01% 15.07% 18.05% 22.29% 12.53%

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Boston Scientific Corp. operating income (loss) as a percentage of net sales increased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.
Income (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Boston Scientific Corp. income (loss) before income taxes as a percentage of net sales increased from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Boston Scientific Corp. net income (loss) as a percentage of net sales decreased from Q3 2022 to Q4 2022 but then increased from Q4 2022 to Q1 2023 exceeding Q3 2022 level.